In line with its own expectations, Netherlands-based biomedical companyIsoTis NV says operating losses increased to 7.1 million euros ($6.4 million) for the first six months of 2001, compared with 3.4 million euros in the like, year-earlier period. Total revenues for the half-year were up 13.6% at 1.2 million, largely due to a substantial increase in government grants, up from 670,000 euros to nearly 1.1 million euros, the firm notes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze